ClinVar Miner

Submissions for variant NM_000051.3(ATM):c.5228C>T (p.Thr1743Ile) (rs587779844)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000220146 SCV000272973 likely pathogenic Hereditary cancer-predisposing syndrome 2017-12-18 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: In silico models in agreement (deleterious) and/or completely conserved position in appropriate species,Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation,Other data supporting pathogenic classification,Detected in individual(s) satisfying established diagnostic criteria for classic disease in trans with a mutation or mutation is homozygous
Color RCV000220146 SCV000904618 uncertain significance Hereditary cancer-predisposing syndrome 2018-09-12 criteria provided, single submitter clinical testing
Counsyl RCV000168297 SCV000800744 uncertain significance Ataxia-telangiectasia syndrome 2018-04-12 criteria provided, single submitter clinical testing
GeneDx RCV000115208 SCV000149117 likely pathogenic not provided 2018-04-23 criteria provided, single submitter clinical testing This variant is denoted ATM c.5228C>T at the cDNA level, p.Thr1743Ile (T1743I) at the protein level, and results in the change of a Threonine to an Isoleucine (ACA>ATA). This variant has been observed in at least four individuals with recessively-inherited Ataxia Telangiectasia (A-T), two individuals with breast cancer, one individual with colon cancer, and as a germline variant in an individual with chronic lymphocytic leukemia (Stankovic 1998, Tavtigian 2009, Reiman 2011, Skowronska 2012, Pearlman 2017). While it is not specified in the literature if ATM Thr1743Ile is on the opposite allele (in trans) as the other identified ATM variant in the individuals with A-T, it has been confirmed as in trans at another clinical laboratory (Stankovic 1998, Reiman 2011, ClinVar SCV000272973.4). Additionally, Barone et al. (2009) reported ATM Thr1743Ile to have reduced, but not absent, kinase activity. ATM Thr1743Ile was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, we consider ATM Thr1743Ile to be a likely pathogenic variant.
Invitae RCV000168297 SCV000218976 uncertain significance Ataxia-telangiectasia syndrome 2018-12-21 criteria provided, single submitter clinical testing This sequence change replaces threonine with isoleucine at codon 1743 of the ATM protein (p.Thr1743Ile). The threonine residue is highly conserved and there is a moderate physicochemical difference between threonine and isoleucine. This variant is present in population databases (rs587779844, ExAC 0.003%). This variant has been reported in individuals affected with ataxia-telangiectasia (A-T) (PMID: 9463314, 21792198, 19147735), chronic lymphocytic leukemia (PMID: 21933854, 17968022), breast cancer (PMID: 19781682) and colon cancer (PMID: 27978560). Whether this variant segregates with disease remains uncertain. ClinVar contains an entry for this variant (Variation ID: 127403). Experimental studies have shown that this missense change causes reduced ATM kinase activity (PMID: 19431188). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.